FDA asks Teva Pharmaceutical for further study on Huntington drug

Israel-based Teva Pharmaceutical Industries said on Tuesday approval for a drug to treat chorea stemming from Huntington disease (HD) has been held up by U.S. regulators seeking further blood study. Teva, the world’s largest generic drugmaker, said it received a letter from the Food and Drug Administration for SD-809 for the treatment of chorea – abnormal, involuntary writhing movements that occur in 90 percent of HD patients at some point in the course of their illness. “The FDA has asked Teva to examine blood levels of certain metabolites.
Go to Source

Alibaba tells vendors to halt drug sales online, cites government rule change

An employee is seen behind a glass wall with the logo of Alibaba at the company's headquarters on the outskirts of Hangzhou, Zhejiang provinceChinese e-commerce firm Alibaba Group Holding Ltd has told vendors on its Tmall website to stop selling medicine, saying a local regulator has issued an "urgent" directive halting drug sales via third-party platforms. Alibaba, in a notice dated May 27 seen by Reuters, cited a circular from the Hebei province branch of the China Food and Drug Administration (CFDA) on "urgent control measures relating to drug products". The regulator&;s surprise directive comes as the government promotes retail sales of over-the-counter (OTC) medicine, with a pledge to harness technology to solve issues as varied as high drug prices and snarling hospital queues.

Go to Source

1 2 3 11